m+Medelevator.RU
← Поиск публикаций
AACE endocrinology and diabetes · 2025

Correlation Between Estimated Glomerular Filtration Rate and Asymptomatic Left Ventricular Diastolic Dysfunction in Patients With Type 2 Diabetes Mellitus.

СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Liu Yemei, Sun Juanjuan, Jiang Jiajia, Li Nanhui, Zhang Wei, Gao Jialin, Ji Xuelei

Аннотация

AIM: To explore the correlation between estimated glomerular filtration rate (eGFR) and asymptomatic left ventricular diastolic dysfunction (ALVDD) in patients with type 2 diabetes mellitus (T2DM).

METHODS: We performed a retrospective study involving 47 ALVDD and 30 non-ALVDD T2DM patients between October 2023 and March 2024. Patient characteristics, laboratory tests, and echocardiographic measurements were recorded. The relationship between eGFR and ALVDD was examined by Spearman correlation and logistic regression analyses. Receiver operating characteristic curve analysis was conducted to test the diagnostic value of eGFR for ALVDD.

RESULTS: Patients with ALVDD had lower eGFR but higher echocardiographic measurements than patients without ALVDD (P < 0.05). The eGFR was negatively correlated with echocardiographic measurements (P < 0.05) and was an independent risk factor for ALVDD. Receiver operating characteristic curve analysis demonstrated that eGFR had an area under the ROC curve of 0.766, with a sensitivity of 63.8%, a specificity of 96.7%, and a threshold of 94.02 mL/min/1.73 m2.

CONCLUSIONS: The eGFR was closely correlated with ALVDD and could be applied to estimate the risk of ALVDD in T2DM patients. We recommend the eGFR be considered when evaluating cardiac diastolic dysfunction in T2DM patients at an early stage and thereby guide prompt clinical intervention.

ИП Урсолов Владлен Сергеевич

ИНН 500118482352 · ОГРНИП 314500117700049

Реквизиты и контакты